Back to Search Start Over

A robust brain network for sustained attention from adolescence to adulthood that predicts later substance use.

Authors :
Weng Y
Kruschwitz J
Rueda-Delgado LM
Ruddy KL
Boyle R
Franzen L
Serin E
Nweze T
Hanson J
Smyth A
Farnan T
Banaschewski T
Bokde ALW
Desrivières S
Flor H
Grigis A
Garavan H
Gowland PA
Heinz A
Brühl R
Martinot JL
Martinot MP
Artiges E
McGrath J
Nees F
Papadopoulos Orfanos D
Paus T
Poustka L
Holz N
Fröhner J
Smolka MN
Vaidya N
Schumann G
Walter H
Whelan R
Source :
ELife [Elife] 2024 Sep 05; Vol. 13. Date of Electronic Publication: 2024 Sep 05.
Publication Year :
2024

Abstract

Substance use, including cigarettes and cannabis, is associated with poorer sustained attention in late adolescence and early adulthood. Previous studies were predominantly cross-sectional or under-powered and could not indicate if impairment in sustained attention was a predictor of substance use or a marker of the inclination to engage in such behavior. This study explored the relationship between sustained attention and substance use across a longitudinal span from ages 14 to 23 in over 1000 participants. Behaviors and brain connectivity associated with diminished sustained attention at age 14 predicted subsequent increases in cannabis and cigarette smoking, establishing sustained attention as a robust biomarker for vulnerability to substance use. Individual differences in network strength relevant to sustained attention were preserved across developmental stages and sustained attention networks generalized to participants in an external dataset. In summary, brain networks of sustained attention are robust, consistent, and able to predict aspects of later substance use.<br />Competing Interests: YW, JK, LR, KR, RB, LF, ES, TN, JH, AS, TF, AB, SD, HF, AG, HG, PG, AH, RB, JM, MM, EA, JM, FN, DP, TP, LP, NH, JF, MS, NV, GS, RW No competing interests declared, TB Served in an advisory or consultancy role for Actelion, Hexal Pharma, Lilly, Lundbeck, Medice, Novartis, Shire. He received conference support or speaker's fee by Lilly, Medice Novartis and Shire. Has been involved in clinical trials conducted by Shire & Viforpharma. Received royalities from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press. The present work is unrelated to the above grants and relationships, HW Received a speaker honorarium from Servier (2014)<br /> (© 2024, Weng et al.)

Details

Language :
English
ISSN :
2050-084X
Volume :
13
Database :
MEDLINE
Journal :
ELife
Publication Type :
Academic Journal
Accession number :
39235858
Full Text :
https://doi.org/10.7554/eLife.97150